Compass Therapeutics (CMPX) Cash & Current Investments (2023 - 2025)
Historic Cash & Current Investments for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $220.5 million.
- Compass Therapeutics' Cash & Current Investments rose 6214.09% to $220.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $220.5 million, marking a year-over-year increase of 6214.09%. This contributed to the annual value of $127.3 million for FY2024, which is 1650.98% down from last year.
- As of Q3 2025, Compass Therapeutics' Cash & Current Investments stood at $220.5 million, which was up 6214.09% from $101.5 million recorded in Q2 2025.
- Over the past 5 years, Compass Therapeutics' Cash & Current Investments peaked at $220.5 million during Q3 2025, and registered a low of $101.5 million during Q2 2025.
- For the 3-year period, Compass Therapeutics' Cash & Current Investments averaged around $152.8 million, with its median value being $152.5 million (2023).
- Over the last 5 years, Compass Therapeutics' Cash & Current Investments had its largest YoY gain of 6214.09% in 2025, and its largest YoY loss of 3570.35% in 2025.
- Over the past 3 years, Compass Therapeutics' Cash & Current Investments (Quarter) stood at $152.5 million in 2023, then decreased by 16.51% to $127.3 million in 2024, then surged by 73.2% to $220.5 million in 2025.
- Its Cash & Current Investments was $220.5 million in Q3 2025, compared to $101.5 million in Q2 2025 and $113.2 million in Q1 2025.